Aptose Biosciences, Inc.
APTO
APTO was delisted on the 1st of April, 2025.
64 hedge funds and large institutions have $85.8M invested in Aptose Biosciences, Inc. in 2021 Q3 according to their latest regulatory filings, with 11 funds opening new positions, 23 increasing their positions, 20 reducing their positions, and 10 closing their positions.
15% more repeat investments, than reductions
Existing positions increased: 23 | Existing positions reduced: 20
10% more first-time investments, than exits
New positions opened: 11 | Existing positions closed: 10
2% more funds holding
Funds holding: 63 → 64 (+1)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
32% less call options, than puts
Call options by funds: $251K | Put options by funds: $370K
42% less capital invested
Capital invested by funds: $148M → $85.8M (-$62.3M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
6CM
683 Capital Management
New York
|
+$2.56M |
| 2 |
Morgan Stanley
New York
|
+$2.47M |
| 3 |
Renaissance Technologies
New York
|
+$2.01M |
| 4 |
SMH
Sanders Morris Harris
Houston,
Texas
|
+$1.19M |
| 5 |
DS
DRW Securities
Chicago,
Illinois
|
+$1.16M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
O
OrbiMed
New York
|
-$15.1M |
| 2 |
EAM
Eventide Asset Management
Boston,
Massachusetts
|
-$7.63M |
| 3 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
-$2.24M |
| 4 |
OM
Opaleye Management
Boston,
Massachusetts
|
-$1.2M |
| 5 |
VC
Voss Capital
Houston,
Texas
|
-$981K |
APTO Hedge Fund Activity: Q3 2021 in Review
64 of the 5,712 institutional investors tracked by Wall St. Rank reported a position in Aptose Biosciences, Inc. (APTO) for Q3 2021, worth a combined $85.8M — down 42% from $148M a quarter earlier.
Buyers outnumbered sellers: 11 funds opened new APTO positions and 10 closed out — a net gain of 1 holder — while 23 added to existing stakes and 20 trimmed.
The largest buyer was 683 Capital Management, adding an estimated $2.56M. The largest seller was OrbiMed, cutting an estimated $15.1M.
- 64 institutional investors held Aptose Biosciences, Inc. (APTO) as of Q3 2021, up from 63 in Q2 2021.
- Funds reported $85.8M of Aptose Biosciences, Inc. stock for Q3 2021, down 42% quarter-over-quarter.
- 11 funds opened new Aptose Biosciences, Inc. positions in Q3 2021 and 10 closed out, a net change of +1 holder.
- The largest Aptose Biosciences, Inc. buyer in Q3 2021 was 683 Capital Management, an estimated $2.56M added.
- The largest Aptose Biosciences, Inc. seller in Q3 2021 was OrbiMed, an estimated $15.1M sold.
Based on aggregated 13F filings for Q3 2021.